WO2000077234A2 - Procedimiento de produccion de licopeno - Google Patents
Procedimiento de produccion de licopeno Download PDFInfo
- Publication number
- WO2000077234A2 WO2000077234A2 PCT/ES2000/000202 ES0000202W WO0077234A2 WO 2000077234 A2 WO2000077234 A2 WO 2000077234A2 ES 0000202 W ES0000202 W ES 0000202W WO 0077234 A2 WO0077234 A2 WO 0077234A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fermentation
- trispora
- lycopene
- carotene
- trisporic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P23/00—Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
Definitions
- the present invention relates to a new method for obtaining carotenoids, especially lycopene, from submerged cultures of mucoral Blakeslea fungi.
- a fermentation method is described that allows an increase in lycopene production, based on the addition of extracts enriched in trisporic acids.
- the process is carried out from wild lines, or mutants thereof, in simple or mixed culture.
- the addition of trisporic acids can be done at the beginning or during fermentation.
- Carotenoids are abundant compounds in fruits and vegetables, and have been the subject of numerous studies due to their properties as antioxidants and as precursors of vitamin A. Lycopene, in addition to its antioxidant property, prevents cardiovascular diseases and some types of cancer such as prostate and gastrointestinal and acts in growth control (Stahl W. and Sies, H. 1996. Arch.
- Carotenoids due to their yellow to red coloration are also used as a supplement and food coloring of margarine, butter, salad oils, soups, sauces (Ninet L. and Renaut J. 1979. In:
- Lycopene is a carotenoid that is produced as an intermediary in the biosynthetic pathway of ⁇ -carotene and xanthophylls.
- Lycopene preparations are obtained from tomato (PCT Patents WO 97/48287, EP 608027), or by fermentation of mucoral fungi such as Phycomyces, Blakeslea and Choanephora (Patents GB 1008469, US 3097146, US 3369974, JP 73016189, JP 73016190 and RU 2102416). Patents GB 1008469 and US 3097146 describe a method of fermentation of the Blakeslea t ⁇ spora gnome consisting of a culture medium whose pH is maintained above 7.0 and up to 9.5. After seven days of incubation, 9.97 mg of lycopene is obtained per 100 ml of medium.
- JP 73016189 and JP 73016190 describe a method of fermentation with mucoral fungi such as Phycomyces, Blakeslea and Choanephora, in which tertiary amines are added to prevent the formation of ⁇ -carotene and promote the accumulation of lycopene.
- tertiary amines are cited: hordenine, 2-dmetmetlamine ethanol; 3-d ⁇ met ⁇ lam ⁇ no-l-propanol; l-d ⁇ met ⁇ lam ⁇ no-2-propanol; 2- diet lammo-ethanol; 3-d ⁇ et ⁇ lam ⁇ no-l-propanol; 1-d ⁇ et ⁇ lammo-2-propanol; triethylamma; 2-d ⁇ soprop ⁇ lam ⁇ no-ethanol; 3- d ⁇ soprop ⁇ lammo-1-propanol; l-d ⁇ soprop ⁇ lam ⁇ no-2-propanol; 2-d ⁇ -n-prop ⁇ lam ⁇ no ethanol; 3-d ⁇ -n-prop ⁇ lammo 1-propanol; 1- d ⁇ -n-prop ⁇ lam ⁇ no-2-propanol; 2-d ⁇ met ⁇ lam ⁇ noet ⁇ lbenzene; 2 diet lammoethylbenzene;
- RU 2102416 describes the addition of aminomethylpindins and tobacco residues to induce the accumulation of lycopene.
- other heterocyclic nitrogen bases capable of blocking the synthesis of carotenoids at the level of lycopene, such as nicotine
- Japanese patent JP 09313167 the use of other heterocyclic nitrogen bases capable of blocking the synthesis of carotenoids at the level of lycopene, such as nicotine
- Japanese patent JP 09313167 imidazole, pyridma, morpholma, quinoline and some substituted derivatives has been described.
- US Patent 3369974 Ninet L., Renaut J. 1979. In: Peppler HJ, Perl an D (eds.) Microbial Technology, 2 nd . Edn, vol. 1 Academic Press, NY, pp. 529-544).
- Trispora Phycomyces blakesleanus and Mucor mucedo, since in addition to stimulating the production of ⁇ -carotene, they stimulate the formation of zygophores (van den Ende, H. 1968. J. Bacteriology 96: 1298-1303; Austin DJ., Bu'Lock JD., Gooday GW 1969. Nature 223: 1178-1179; Reschke, T. 1969. Tetrahedron Letters 29: 3435-3439; van den Ende H., Wiechmann AHCA., Reyngoud DJ., Hendricks T. 1970. J. Bacteriology 101: 423-428).
- trisporic acids are oxidized and unsaturated derivatives of 1,1,3-trimethyl-2- (3-methyloctyl) cyclohexane. Such compounds can be classified as processed sesquiterpenes or degradation products of diterpenes or carotenoids.
- the trisporic acids have been characterized as a mixture of three substances: acid trisporic A, B and C, also called ⁇ factor, ⁇ : and ⁇ 3 (owing to stimulate the synthesis of ⁇ -carotene)
- the most abundant is the acid trisphoric C, which is present in 80% in mixed cultures of B. Trispora (Caglioti, L., Cainelli, G., Camerino, B. Mondelli, R., Prieto, A., Quilico, A., Salvatori, T, Selva, A. 1966, Tetrahedron Supplement 7: 175-187).
- Trisporic acids are synthesized from ⁇ -carotene produced by both the (+) and the (-) lines. ⁇ -carotene is metabolized via retinal in 4- hydrotrisporol. This compound is metabolized by lineage
- These two intermediaries are converted into trisphoric acid only after diffusing in the medium until the lineage of the opposite sex (Compiled by Gooday GW. And Carlile MJ. 1997. Mycologist 11: 26-30). That is, the lineage (-) produces the intermediates that are converted into trisphoric acid by the lineage (+) and vice versa, according to the previous scheme.
- Trisporic acids obtained from mixed cultures of B. Trispora can be used to increase the production of ⁇ -carotene in cultures with independent strains. For example, the addition of 21.8 units of factor ⁇ increases by 422% the production of ⁇ -carotene from the lineage (-) and 71% production from the lineage (+). However, the stimulation of carotenogenesis per unit of ⁇ factor in lineage cultures (-) it was only 20-30% of the carotenogenesis produced in mixed cultures and with similar amounts of factor ⁇ . (Sutter RP. And Rafelson ME. 1968. J. Bacteriology 95: 426-432). The purification of trisporic acids can be carried out by various methods, such as those described by Sutter, R. 1970.
- Lycopene production is based on suppressing the lycopene cyclase activity that converts lycopene into ⁇ -carotene, which results in low levels of ⁇ -carotene in fermentation.
- Trisporic acids are synthesized from ⁇ -carotene, which are the sex hormones that induce carotenogenesis.
- the object of the present invention aims to increase the production of carotenoids, especially lycopene, in a fermentation process with mucoral fungi ⁇ Blakeslea, Choanephora or Phycomyces), more specifically in B. Trispora
- the invention consists in cultivating the fungus B. trispora in a fermentation medium and add partially purified trisporic acids (or ⁇ factor) (PTA) or either unpurified (NPTA) from any other source, such as from a production broth of ⁇ -carotene.
- PTA partially purified trisporic acids
- NPTA unpurified
- the effect of trisporic acids on the fermentation of lycopene is based on the fact that these hormones are synthesized from ⁇ -carotene, a compound that does not form in the fermentation of lycopene. Under these conditions the fungus lacks a precursor for the synthesis of these hormones and carotenogenesis is not induced to its maximum extent.
- the organisms used for fermentation can be isolated strains or a mixture of the (+) and (-) strains of mucoral fungi, more specifically B. trispora, or mutants of B. Trispora capable of accumulating lycopene.
- Several mixtures of (+) and (-) line of the fungus can be used in the fermentation process of this invention. In the case of using strains of B.
- trispora producing ⁇ -carotene compounds capable of blocking carotenogenesis at the lycopene level (for example tertiary amines and others mentioned above) are added. In the case of using mutants blocked in the biosynthesis of carotenoids from lycopene, the addition of tertiary amines and related compounds will not be necessary.
- trisporic acids are added partially purified (PTA) or unpurified (NPTA) from any source thereof, such as from culture medium from a ⁇ -carotene fermentation , and in both cases at an approximate concentration of 0.35 mg / ml.
- PTA partially purified
- NPTA unpurified
- the term NPTA corresponds to a broth of ⁇ -carotene.
- the concentration in said broths of trisporic acids can be calculated according to the day of incubation (on the 4th day it will be between 350-400 ⁇ g / ml).
- the process for the production of carotenoids from mucoral fungi, more specifically lycopene with selected strains or B mutants. trispora can be carried out in any culture medium that contains one or more carbon sources, one or more sources of nitrogen, mineral salts and thiamine.
- Carbon sources can be added as simple or complex nutrients and include carbohydrates or fats, such as dextrins, starches, glucose, sucrose, fructose, animal or vegetable oils.
- the culture medium must also carry an assimilable source of nitrogen, organic or inorganic, such as soybean meal, cornmeal, soluble distillates, yeast extract, cotton flour, peptone, casein, ammonium sulfate and others.
- an assimilable source of nitrogen, organic or inorganic such as soybean meal, cornmeal, soluble distillates, yeast extract, cotton flour, peptone, casein, ammonium sulfate and others.
- mineral salts that can be added to the culture medium are phosphates, sulfates, chlorides, sodium, potassium, ammonium, calcium, magnesium. Nutrient ratios are determined based on the growth needs of the microorganism and production levels. Fermentation is preferably carried out under aerobic conditions and in submerged culture.
- the fermentation temperature may range between 20 and 32 ° C, although between 25 and 28 ° C is preferred.
- trisporic acids can be carried out from a partially purified preparation or from any source thereof, such as culture medium from a fermentation of ⁇ -carotene of any mucoral fungus.
- Lycopene is extracted using any described method of cell breakage that allows the intracellular content to be released, which is solubilized in any solvent in which it is soluble. Its concentration can be determined by spectrophotometric measurement, but it can be he prefers the use of liquid chromatography (HPLC), by any of the methods described in the literature.
- mutants producing ⁇ -carotene ASA2 (+) and ASA25 (-). Lycopene mutant SB34 (-). The latter mutant also produces 25% of ⁇ -carotene (see table 1).
- the choice of mutants is irrelevant from the point of view of the effect of increased carotene production due to trisporic acids per se. That is, the effect due to said compounds would be reproducible in any other analogous mutant strain, even if it had a lower basal lycopene production, which occurs with parental strains, for example.
- the parental strains are deposited in a collection and are viable and accessible to the public.
- An inoculum medium is prepared containing per liter: soybean meal, 23 g; cornmeal, 47 g; 0.5 g monopotassium phosphate; Thiamine hydrochloride, 0.002 g. Its initial pH is 6.3. The medium is distributed in 500 ml Erlenmeyer flasks at a rate of 67 or 100 ml. After sterilization, strains B are seeded from spore suspensions. trispora ASA2 (+) and B. Trispora ASA25 (-) in separate flasks and incubated at 25 ° C for 48 hours. The mutant strains B. trispora ASA2 (+) and B. trispora ASA25 (-) are obtained by mutation with NTG from wild B strains. trispora F208 (-) and F117 (+) deposit All of the Industrial Microorganisms Collection (VKM), located in Moscow, Russia, both strains being accessible to the public.
- VKM Industrial Microorganisms Collection
- a base fermentation medium is prepared containing per liter: soy flour, 44 g; cornmeal, 19 g; dibasic phosphate 0.55 g; thiamine hydrochloride, 0.002 g; 10% vegetable oil Its initial pH is adjusted to 7.5 with potassium hydroxide. The medium is distributed in 250 ml Erlenmeyer flasks at a rate of 20 ml. For the fermentation of ⁇ -carotene, flasks containing base medium with 10% of a mixed culture of the B strains are inoculated. trispora ASA2 (+) and B. trispora ASA25 (-).
- a chemical agent is added to the base medium in order to block the biosynthetic pathway at the lycopene level, such as 2 ml / 1 pyridine.
- This medium is inoculated with 10% of a mixed culture of the B lines. trispora ASA2 (+) and B. trispora ASA25 (-). All flasks are incubated at 25 ° C on an orbital shaker at 250 rpm. From the second day of fermentation, a sample is taken every 24 hours and the concentration of trisporic acids in ⁇ -carotene producing flasks and in lycopene producing flasks is determined.
- the determination of the concentration of trisporic acids is carried out by extraction with a volume of chloroform after acidifying the sample to pH 2.
- the organic fraction is extracted with a volume of a 4% sodium bicarbonate solution, the aqueous phase, which is acidified to extract it again with chloroform.
- the chloroform is evaporated to dryness and the residue constituted by trisporic acids is dissolved in ethanol or Tris-sulfate buffer.
- Trisporic acids are quantified by spectrophotometric absorbance measurement at 325 nm, assuming a coefficient of absorptivity of 70 ml x mg "1 x era " 1 (Sutter RP., Capage DA., Harrison TL., Keen WA. 1973. J. Bacteriology 114: 1074-1082).
- the inoculum medium is carried out in the manner described in Example 1. After sterilization, strain B is sown from a spore suspension. trispora SB34 (-) and incubate at 25 ° C for 48 hours. The mutant strain B. trispora SB34 (-) was obtained by mutation with NTG from the wild JB line. Trispora F921 (-) deposited in the VKM crop collection, Moscow, Russia and accessible to the public.
- a fermentation medium is prepared in the same manner as described in example 1. After sterilization, a series of flasks are inoculated with 10% of the B line. trispora SB34 (-), which is characterized as a mutant partially blocked in the biosynthesis of ⁇ -carotene so that it accumulates lycopene. All flasks are incubated at 25 ° C on an orbital shaker at 250 rp.
- Control flasks are those that do not carry the addition of trisporic acids.
- the flask group that receives Addition of trisporic acids is maintained under the same conditions as the control until the 4th day when a preparation enriched in trisporic acids, purified as described in Example 1, is added at a final concentration of 350 ⁇ g / ml.
- the inoculum medium is carried out in the manner described in Example 1. After sterilization, strain B is seeded from spore suspension. trispora ASA25 (-) and incubate at 25 ° C for 48 hours.
- a fermentation medium is prepared in the same manner as described in example 1. After sterilization a chemical agent is added that blocks the biosynthesis of carotenoids at the level of lycopene, such as imidazole at a final concentration of 0.75 mg / ml. This medium is also supplemented with phosphate buffer pH 7.5 at a final concentration of 25 mM and inoculated with 10% of the B line. trispora ASA25 (-). The flasks are incubated at 25 ° C on an orbital shaker at 250 rpm.
- Control flasks are those that do not carry the addition of trisporic acids.
- the flask group that receives addition of trisporic acids is maintained in the same con- Dicions that control until the 4th day when a preparation enriched in trisporic acids is added to a final concentration of 350 ⁇ g / ml.
- the purification of trisporic acids is carried out in the same manner described in example 1.
- the inoculum medium is carried out in the manner described in Example 1. After sterilization, the B strains are seeded from spore suspensions. trispora ASA25 (-) and B. Trispora ASA2 (+) in separate flasks and incubate at 25 ° C for 48 hours.
- a fermentation medium is prepared in the same manner as described in example 1. After sterilization imidazole is added at a final concentration of 0.75 mg / ml and phosphate buffer pH 7.5 at a final concentration of 25 mM. This medium is inoculated with 10% of a mixture of the B strains. trispora ASA25 (-) and B. trispora ASA2 (+). The flasks are incubated at 25 ° C on an orbital shaker at 250 rpm. To obtain a source of unpurified trisporic acids (NPTA), a fermentation medium is prepared in the same way as described in Example 1. After sterilization a mixed culture is planted with 10% of the strains of B. trispora ASA2 (+) and B. trispora ASA25 (-), producers of ⁇ -carotene. The flasks are incubated at 25 ° C on an orbital shaker at 250 rpm.
- NPTA unpurified trisporic acids
- Control flasks are those that do not carry the addition of trisporic acids.
- the flask group that receives the addition of partially purified trisporic acids (PTA), is maintained in the same conditions as the control until the 4th day when trisporic acids are added at a final concentration of 350 ⁇ g / ml.
- the purification of trisporic acids is carried out in the same manner as described in example 1.
- the flask group that receives the addition of unpurified trisporic acids (NPTA) is maintained under the same conditions as the control until the 4th day, for then be subjected to a filtration process through a 20 ⁇ m nylon filter that allows to separate the mycelium from the B strains.
- trispora ASA2 (+) of the culture medium where they have grown in the presence of imidazole In parallel, the separation of mycelium and culture medium is carried out through a 20 ⁇ m nylon filter, but in this case of flasks containing the two strains B. trispora ASA2 (+) and B. trispora ASA25 (-), under conditions of ⁇ -carotene production, whose culture medium is considered an unpurified source of trisporic acids (NPTA). After the separation of mycelium and culture medium, the mycelium of the B strains is mixed. trispora ASA25 (-) and ASA2 (+) grown with imidazole, with the culture medium of the same strains grown in the absence of imidazole.
- Imidazole is added to the culture medium considered as an unpurified source of trisphoric acids (NPTA) to obtain a final concentration of 0.75 mg / ml. These flasks are incubated at 25 ° C and 250 rpm. With the addition of partially purified trisphoric acids (PTA), an increase of 29.14 to 43.58 mg of lycopene per gram of dry weight is achieved (a 50% increase over the control on the 6th day of fermentation, Fig. 3) and by adding ⁇ -carotene culture medium an increase of 29.14 to 41.07 mg of lycopene per gram of dry weight is achieved (an increase of 41% over the control on the 6th day of fermentation , Fig. 4). This example demonstrates that the effect of trisporic acids is independent of their degree of purification.
- the inoculum medium is carried out in the manner described in Example 1. After sterilization, the B strains are seeded from spore suspensions. trispora SB3 (-) and B. Trispora ASA2 (+) in separate flasks and incubate at 25 ° C for 48 hours.
- a fermentation medium is prepared in the same manner as described in Example 1. After sterilization, it is inoculated with 10% of a mixture of the B. trispora SB34 (-) and B strains. trispora ASA2 (+). The flasks are incubated at 25 ° C on an orbital shaker at 250 rpm.
- Control flasks are those that do not carry the addition of trisporic acids.
- the flask group that receives the addition of trisporic acids is maintained under the same conditions as the control until the 4th day in which a preparation enriched in trisporic acids is added at a final concentration of 350 ⁇ g / ml.
- Acid purification Trisporic is performed in the same manner described in Example 1.
- the inoculum medium is carried out in the manner described in Example 1. After sterilization, the B strains are seeded from spore suspensions. trispora SB34 (-), B. trispora ASA25 (-) and B. Trispora ASA2 (+) in separate flasks and incubate at 25 ° C for 48 hours.
- a fermentation medium is prepared in the same manner as described in Example 1. After sterilizing this medium is separated into two groups. A group of flasks is inoculated with 10% of a mixture of the B strains. trispora SB34 (-) and B. trispora ASA2 (+). To the other group of flasks, after sterilization, imidazole is added at a final concentration of 0.75 mg / ml and phosphate buffer pH 7.5 at a final concentration of 25 mM. This medium is inoculated with 10% of a mixture of the B strains. trispora ASA25 (-) and B. trispora ASA2 (+). All flasks are incubated at 25 ° C on an orbital shaker at 250 rpm.
- Control flasks are those that do not carry the addition of trisporic acids.
- the flask group that receives addition of trisporic acids is maintained under the same conditions as the control until the 4th day when a preparation enriched in trisporic acids is added at a concentration final traction of 350 ⁇ g / ml.
- the purification of trisporic acids is carried out in the same manner described in example 1.
- Table 1 Percentage of carotenoids at the 5th and 6th day of fermentation in mixed culture of the B strains. trispora SB34 (-) or ASA25 (-) with B. trispora ASA 2 (+)
- ASA25 (-), whose carotenoid mixture contains only 2% of ⁇ -carotene (Examples 4 and 6).
- trispora SB34 (-), whose carotenoid mixture contains more than 20% of ⁇ -carotene (Examples 5 and 6).
- FIG. 1 Concentration of trisporic acids along a fermentation of ⁇ -carotene and a fermentation of lycopene. In both fermentations a mixed culture of the B strains is used. trispora ASA25 (-) and B. trispora ASA2 (+). In the fermentation of lycopene (squares) a chemical agent is added to the culture medium that favors the accumulation of lycopene, in this case pyridine. The fermentation of ⁇ -carotene (rhombuses) is carried out under the same conditions but without pyridine. Abcisas: time in days; Ordered: concentration of trisporic acids ( ⁇ g / ml).
- FIG. 3 Lycopene production by mutant line B. trispora ASA25 (-), superproducer of ⁇ -carotene, with and without the addition of trisporic acids.
- the fermentation medium is supplemented with imidazole to favor the accumulation of lycopene.
- the lycopene production values obtained in a control fermentation without the addition of trisporic acids are represented by rhombuses.
- the effect of the addition of partially purified trisphoric acids (PTA) on the 4th day of fermentation on lycopene production is indicated by squares. The values represent the average of two independent samples. Error bars represent the deviation average standard. Abcisas: time in days; Sorted: mg lycopene / g dry weight.
- FIG. 4 Production of lycopene in mixed culture of the superproductive mutant strains of ⁇ -carotene B. trispora ASA25 (-) and B. trispora ASA2 (+), with and without the addition of trisporic acids.
- the fermentation medium is supplemented with imidazole to favor the accumulation of lycopene.
- Lycopene production values obtained in a control fermentation without the addition of trisporic acids are represented by diamonds.
- the effect of the addition of partially purified trisporic acids (PTA) on the 4th day of fermentation on lycopene production is indicated by squares.
- the production of lycopene obtained by the addition of unpurified trisporic acids (NPTA) on the 4th day of fermentation is represented by circles.
- the values represent the average of two independent samples. Error bars represent the standard deviation of the average.
- Abcisas time in days; Sorted: mg lycopene / g dry weight.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- External Artificial Organs (AREA)
- Glass Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU50792/00A AU5079200A (en) | 1999-06-09 | 2000-06-06 | Lycopen production method |
AT00935226T ATE308622T1 (de) | 1999-06-09 | 2000-06-06 | Herstellungsverfahren für lycopen |
JP2001503676A JP3904924B2 (ja) | 1999-06-09 | 2000-06-06 | リコペンを製造する方法 |
DE60023693T DE60023693T2 (de) | 1999-06-09 | 2000-06-06 | Herstellungsverfahren für lycopen |
EP00935226A EP1184464B1 (en) | 1999-06-09 | 2000-06-06 | Lycopen production method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009901271A ES2156735B1 (es) | 1999-06-09 | 1999-06-09 | Procedimiento de produccion de licopeno. |
ESP9901271 | 1999-06-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000077234A2 true WO2000077234A2 (es) | 2000-12-21 |
WO2000077234A3 WO2000077234A3 (es) | 2001-02-08 |
Family
ID=8308761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2000/000202 WO2000077234A2 (es) | 1999-06-09 | 2000-06-06 | Procedimiento de produccion de licopeno |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1184464B1 (es) |
JP (1) | JP3904924B2 (es) |
CN (1) | CN1252276C (es) |
AT (1) | ATE308622T1 (es) |
AU (1) | AU5079200A (es) |
DE (1) | DE60023693T2 (es) |
ES (2) | ES2156735B1 (es) |
WO (1) | WO2000077234A2 (es) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003056028A1 (es) | 2001-12-31 | 2003-07-10 | Vitatene, S.A. | Procedimiento mejorado de produccion de licopeno mediante la fermentacion de cepas seleccionadas de blakeslea trispora, formulaciones y usos del licopeno obtenido |
US6989257B2 (en) | 2001-06-06 | 2006-01-24 | Dsm Ip Assets B.V. | Isoprenoid production |
CN1330746C (zh) * | 2001-10-29 | 2007-08-08 | Dsmip资产有限公司 | 无外源胡萝卜素生成抑制剂条件下在适宜培养基中生产高产量番茄红素的三孢布拉霉 |
WO2012159446A1 (zh) | 2011-05-20 | 2012-11-29 | 浙江医药股份有限公司新昌制药厂 | 一种发酵法生产天然β-胡萝卜素的方法和应用 |
WO2024022771A1 (en) | 2022-07-29 | 2024-02-01 | Givaudan Sa | Composition comprising a polyketide pigment |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004063359A2 (de) * | 2003-01-09 | 2004-07-29 | Basf Aktiengesellschaft | Verfahren zur herstellung von carotinoiden oder deren vorstufen mittels gentechnisch veränderter organismen der gattung blakeslea, mit dem verfahren hergestellte carotinoide oder deren vorstufen und deren verwendung |
JP2006513729A (ja) * | 2003-01-09 | 2006-04-27 | ビーエーエスエフ アクチェンゲゼルシャフト | Blakeslea属の生物の遺伝子改変方法、それに関連して生じる生物およびその使用 |
CN100335642C (zh) * | 2005-03-16 | 2007-09-05 | 佛山市英迈瑞生物技术服务有限公司 | 基因重组毕赤酵母生产番茄红素的方法 |
CN102140052B (zh) * | 2010-12-30 | 2013-12-18 | 南京工业大学 | 一种连续提取番茄红素的方法 |
CN102251008B (zh) * | 2011-06-09 | 2013-05-29 | 北京化工大学 | 一种提高由三孢布拉氏霉菌生产番茄红素产量的方法 |
CN109280685B (zh) * | 2017-07-21 | 2021-11-23 | 浙江医药股份有限公司新昌制药厂 | 通过增加天然类胡萝卜素发酵过程中溶氧生产天然类胡萝卜素的方法 |
CN108004272B (zh) * | 2017-12-28 | 2021-09-21 | 嘉必优生物技术(武汉)股份有限公司 | 一种利用三孢布拉氏霉菌制备番茄红素的方法及番茄红素制品 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1034944A (en) * | 1963-08-02 | 1966-07-06 | Farmaceutici Italia | Production of ª‰-carotene |
GB1114043A (en) * | 1964-09-23 | 1968-05-15 | Upjohn Co | Improvements in or relating to acid compounds and the manufacture thereof by a microbiological method |
-
1999
- 1999-06-09 ES ES009901271A patent/ES2156735B1/es not_active Expired - Fee Related
-
2000
- 2000-06-06 DE DE60023693T patent/DE60023693T2/de not_active Expired - Lifetime
- 2000-06-06 AU AU50792/00A patent/AU5079200A/en not_active Abandoned
- 2000-06-06 EP EP00935226A patent/EP1184464B1/en not_active Expired - Lifetime
- 2000-06-06 ES ES00935226T patent/ES2252009T3/es not_active Expired - Lifetime
- 2000-06-06 JP JP2001503676A patent/JP3904924B2/ja not_active Expired - Fee Related
- 2000-06-06 AT AT00935226T patent/ATE308622T1/de not_active IP Right Cessation
- 2000-06-06 WO PCT/ES2000/000202 patent/WO2000077234A2/es active IP Right Grant
- 2000-06-06 CN CN00808484.XA patent/CN1252276C/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1034944A (en) * | 1963-08-02 | 1966-07-06 | Farmaceutici Italia | Production of ª‰-carotene |
GB1114043A (en) * | 1964-09-23 | 1968-05-15 | Upjohn Co | Improvements in or relating to acid compounds and the manufacture thereof by a microbiological method |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6989257B2 (en) | 2001-06-06 | 2006-01-24 | Dsm Ip Assets B.V. | Isoprenoid production |
US7232679B2 (en) | 2001-06-06 | 2007-06-19 | Dsm Ip Assets B.V. | Isoprenoid production |
CN1330746C (zh) * | 2001-10-29 | 2007-08-08 | Dsmip资产有限公司 | 无外源胡萝卜素生成抑制剂条件下在适宜培养基中生产高产量番茄红素的三孢布拉霉 |
WO2003056028A1 (es) | 2001-12-31 | 2003-07-10 | Vitatene, S.A. | Procedimiento mejorado de produccion de licopeno mediante la fermentacion de cepas seleccionadas de blakeslea trispora, formulaciones y usos del licopeno obtenido |
JP2005512599A (ja) * | 2001-12-31 | 2005-05-12 | ビタテネ、ソシエダッド アノニマ | ブラケスレアトリスポラの選択された菌株の発酵による改善されたリコペン産生方法、このようにして得たリコペンの調合物及び使用 |
JP2009171973A (ja) * | 2001-12-31 | 2009-08-06 | Vitatene Sa | ブラケスレアトリスポラの選択された菌株の発酵による改善されたリコペン産生方法、このようにして得たリコペンの調合物及び使用 |
EP2143800A1 (en) | 2001-12-31 | 2010-01-13 | Vitatene, S.A. | Formulations of lycopene and uses thereof |
WO2012159446A1 (zh) | 2011-05-20 | 2012-11-29 | 浙江医药股份有限公司新昌制药厂 | 一种发酵法生产天然β-胡萝卜素的方法和应用 |
WO2024022771A1 (en) | 2022-07-29 | 2024-02-01 | Givaudan Sa | Composition comprising a polyketide pigment |
Also Published As
Publication number | Publication date |
---|---|
ES2156735A1 (es) | 2001-07-01 |
WO2000077234A3 (es) | 2001-02-08 |
JP3904924B2 (ja) | 2007-04-11 |
JP2003502052A (ja) | 2003-01-21 |
CN1252276C (zh) | 2006-04-19 |
CN1353765A (zh) | 2002-06-12 |
EP1184464B1 (en) | 2005-11-02 |
DE60023693T2 (de) | 2006-07-20 |
ATE308622T1 (de) | 2005-11-15 |
DE60023693D1 (de) | 2005-12-08 |
ES2156735B1 (es) | 2002-02-16 |
EP1184464A2 (en) | 2002-03-06 |
AU5079200A (en) | 2001-01-02 |
ES2252009T3 (es) | 2006-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0635576B1 (en) | Bacteria belonging to new genus and process for production of carotenoids using same | |
ES2252009T3 (es) | Metodo de produccion de licopeno. | |
JP4463347B2 (ja) | 飼料添加用色素含有物 | |
JPH05508532A (ja) | ゼアキサンチン及びゼアキサンチン含有組成物の製造 | |
CN102186984A (zh) | 类胡萝卜素的发酵法 | |
US20080293097A1 (en) | Biological Production of Zeaxanthin and Carotenoid Biosynthesis Control | |
AU2004274750B2 (en) | Process for producing carotenoid compound | |
ES2336199T3 (es) | Blakeslea trispora productora de un rendimiento elegvado de licopeno en un medio adecuado en ausencia de un inhibidor exogeno de la carotenogenesis. | |
JP2007244205A (ja) | カロテノイド類の製造方法 | |
JP4290559B2 (ja) | ブラケスレアトリスポラ(Blakesleatrispora)の(+)株及び(−)株を使用する混合培養物の発酵によるβ−カロテンの生産方法 | |
EP1956077A1 (en) | Novel microorganism and method for producing carotenoid using the same | |
MXPA04007367A (es) | Procedimiento de produccion de astaxantina mediante la fermentacion de cepas seleccionadas de xanthophyllomyces dendrorhous. | |
JP5838552B2 (ja) | 新規微生物及びそれを用いたカロテノイドの生産方法 | |
Kalingan et al. | Application of agro-industrial by-products for riboflavin production by Eremothecium ashbyii NRRL 1363 | |
WO2021172372A1 (ja) | シス型キサントフィル組成物および使用方法 | |
JP4847799B2 (ja) | 新規微生物、および新規カロテノイドの製造方法 | |
EP0449051B1 (en) | Novel, physiologically active substances, benastatins A and B, and production and use thereof | |
JP2003304895A (ja) | リコペンの醗酵生産法 | |
US3597324A (en) | Preparation of the antibiotic rifamycin sv | |
JP4935259B2 (ja) | 新規微生物およびそれを用いたカロテノイド類の製造方法 | |
JP2005046027A (ja) | 合成培地を用いたカロテノイドの製造法 | |
Lascelles et al. | [36] Use of mutants of Rhodopseudomonas spheroides for preparation of bacteriochlorophyll precursors | |
JPH05271145A (ja) | 新規生理活性物質ベキノスタチンaおよびb、その製造法およびその用途 | |
JPH05105693A (ja) | Ws4418物質、その製法及び用途 | |
EA002468B1 (ru) | Пара штаммов гетероталличного гриба “blakeslea trispora” всб-129(-) и всб-130(+), продуцирующая ликопин, и способ получения ликопина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00808484.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000935226 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2001 503676 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2000935226 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000935226 Country of ref document: EP |